Completed PHASE2 INTERVENTIONAL 2-arm NCT01614964

Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)

Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13)

Sponsor: Tulane University

Conditions Malaria

Interventions AQ-13 Treatment Coartem Treatment

Updated 8 times since 2017 Last updated: Jun 18, 2024 Started: Aug 31, 2013 Primary completion: Jan 31, 2016 Completion: Feb 28, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Malaria, this trial is completed. The trial is conducted by Tulane University and has accumulated 8 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2024 — Aug 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tulane University
University of the Sciences, Techniques and Technologies of Bamako

Data source: Tulane University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bamako, Mali